Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-1.66||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-8.67|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-20.57%||ROE||-21.41%||ROI|
|Current Ratio||25.65||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.04|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||10 K||Cash From Investing Activities||-20.47 M||Cash From Operating Activities||-7.63 M||Gross Profit|
|Net Profit||-7.86 M||Operating Profit||-7.87 M||Total Assets||96.87 M||Total Current Assets||90.31 M|
|Total Current Liabilities||3.52 M||Total Debt||Total Liabilities||3.77 M||Total Revenue|
|High 52 week||6.75||Low 52 week||2.52||Last close||2.6||Last change||1.96%|
|RSI||26.01||Average true range||0.26||Beta||1.45||Volume||180.6 K|
|Simple moving average 20 days||-15.61%||Simple moving average 50 days||-28.08%||Simple moving average 200 days||-46.18%|
|Performance Week||-4.41%||Performance Month||-36.59%||Performance Quart||-39.53%||Performance Half||-59.25%|
|Performance Year||-59.06%||Performance Year-to-date||-42.22%||Volatility daily||4.51%||Volatility weekly||10.1%|
|Volatility monthly||20.69%||Volatility yearly||71.67%||Relative Volume||2060.39%||Average Volume||340.44 K|
|New High||New Low|
2019-11-12 16:06:00 | Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights
2019-10-19 09:23:18 | Read This Before Selling Calithera Biosciences, Inc. NASDAQ:CALA Shares
2019-10-18 10:23:24 | These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
2019-10-07 09:54:01 | Calithera CALA Completes Enrollment in Mid-Stage RCC Study
2019-09-27 09:28:01 | Calithera Biosciences Enters Oversold Territory
2019-09-26 12:00:04 | Implied Volatility Surging for Calithera CALA Stock Options
2019-09-25 08:05:00 | Calithera to Present at the 2019 Cantor Global Healthcare Conference
2019-09-19 10:06:40 | Calithera Biosciences, Inc. NASDAQ:CALA: Is It Growing Too Fast?
2019-08-23 09:11:52 | Is Calithera Biosciences, Inc.'s NASDAQ:CALA CEO Pay Justified?
2019-08-10 09:57:34 | Edited Transcript of CALA earnings conference call or presentation 8-Aug-19 9:00pm GMT
2019-07-24 10:40:51 | Does Calithera Biosciences, Inc. NASDAQ:CALA Have A High Beta?
2019-06-18 23:00:00 | Calithera Biosciences, Inc. Prices Public Offering of 12,500,000 shares of Common Stock
2019-06-18 13:16:37 | Did You Miss Calithera Biosciences's NASDAQ:CALA 37% Share Price Gain?
2019-06-17 10:04:42 | Calithera's Kidney Cancer Drug Doubles Progression-Free Survival Vs. Chemotherapy
2019-05-14 12:34:47 | Calithera Biosciences, Inc. CALA Q1 2019 Earnings Call Transcript
2019-05-10 18:08:28 | Edited Transcript of CALA earnings conference call or presentation 9-May-19 9:00pm GMT
2019-05-10 05:14:17 | Calithera: 1Q Earnings Snapshot
2019-05-09 16:06:00 | Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights
2019-05-02 10:32:02 | Analysts Estimate Calithera CALA to Report a Decline in Earnings: What to Look Out for
2019-04-25 07:34:54 | How Many Calithera Biosciences, Inc. NASDAQ:CALA Shares Do Institutions Own?
2019-03-27 17:39:09 | Calithera CALA Initiates Phase I/II Study of Telaglenastat
2019-03-07 20:40:17 | Edited Transcript of CALA earnings conference call or presentation 7-Mar-19 9:30pm GMT
2019-03-05 07:05:00 | Calithera to Present at Cowen & Company 39th Annual Healthcare Conference
2019-02-22 08:00:00 | Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
2019-01-28 07:30:00 | Analysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences — Research Highlights Growth, Revenue, and Consolidated Results
2019-01-18 14:19:35 | What Did Calithera Biosciences, Inc.’s NASDAQ:CALA CEO Take Home Last Year?